TRACON Pharmaceuticals Inc

0.00 (-0.38%)
: $0.19 0.00 (1.56%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)5.80M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.5 Million
Adjusted EPS-$0.08
See more estimates
10-Day MA$0.19
50-Day MA$0.18
200-Day MA$0.28
See more pivots

TRACON Pharmaceuticals Inc Stock, NASDAQ:TCON

4350 La Jolla Village Drive, Suite 800, San Diego, California 92122-1243
United States of America
Phone: +1.858.550.0780
Number of Employees: 18


TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.